



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

No Publication of Interventional Phase 3 and 4 Clinical Trials in Radiation Oncology

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-016040
Article Type:	Research
Date Submitted by the Author:	23-Jan-2017
Complete List of Authors:	Pérez-Alija, Jaime; Hospital Plato, Radioterapia i Oncología Gallego, Pedro; Hospital Plato, Radioterapia i Oncología Linares, Isabel; Institut Catala d' Oncologia, Radiotherapy Ambroa, Eva; Consorci Sanitari de Terrassa, Medical Physics Pedro, Agustí; Hospital Plato, Radioterapia i Oncología
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology, Health economics
Keywords:	Radiation oncology < RADIOTHERAPY, Clinical trials < THERAPEUTICS, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, medicine evidence based

SCHOLARONE™
Manuscripts

NO PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN
RADIATION ONCOLOGY

Jaime Pérez-Alija

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

Pedro Gallego Franco *

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

Isabel Linares

Institut Català d'Oncologia

Avinguda de la Granvia, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain

Eva Ambroa

Consorci Sanitari de Terrasa

Carr. Torrebonica, S/N, 08227 Terrassa, Barcelona, Spain

Agustí Pedro

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

***Corresponding Author:**

Email: pedro.gallego@hospitalplato.com

Phone: 0034 666091433

FAX= 0034 934140133

POSTAL ADRESS: C/Plató 21 08006 Barcelona, Spain

KEYWORDS: Oncology, Radiation Oncology, Clinical Trials,

Health Economics, medicine evidence based

Word Count: 3124 Including Abstract and “Strengths and limitations of this Study”.

OBJECTIVES

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. We aimed to determine the rate of non-publication of interventional phase 3 and 4 clinical trials involving cancer patients undergoing radiotherapy.

SETTING

The ClinicalTrials.gov database was searched for interventional phase 3&4 trials in radiotherapy with a primary completion date before 1 January 2013. We determined how many of these registry entries have not published the compulsory deposition of their results in the database and performed a systematic search for published studies in peer-reviewed journals.

RESULTS

Of 483 trials, 414 (85.7%) did not deposit a summary result in the registry. In addition, 44.2% of them did not publish their results in a peer-reviewed journal. Similar percentages were found for most cancer subtypes: brain (38%), breast (34%), cervical (56%), colorectal (33%), lung (46%), prostate (43%), bladder (56%), head and neck (54%), lymphoma (33%).

CONCLUSIONS

Our results show that most trials in radiation oncology did not report the results in the

registry. Almost half of these trials have not been published in the biomedical literature. This means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients

Strengths and limitations of this Study

- We have considered and analyzed the higher levels of evidence-base radiation oncology.
- Each trial meeting the inclusion criteria were independently searched by at least two authors in order to assess its publication in a peer-reviewed journal.
- ClinicalTrials.gov is, by far, the largest trial registry in the world. Any applicable medical device trial or medical drug trial planned to be market on the US has to be registered in this registry.
- Insufficient statistical power and lack of data to test for hypotheses giving a plausible explanation of non-publication in radiation oncology.

BACKGROUND

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All this evidence should be both published and available, since withholding results skews the evidence and therefore dangerously distorts it. Publication of all trials conducted in radiation oncology is needed to fully determine the benefits and risks of treatments currently in use in our clinics.

Since 2005, the International Committee of Medical Journal Editors has required prospective registration of all interventional clinical studies prior to publication. It does not, however, require authors to report the results of registered trials.¹ On the other hand, a US federal law, the Food and Drug Administration Amendments Act of 2007 (FDAAA 801),² requires responsible parties of all interventional trials to submit summary results to the ClinicalTrials.gov database 12 months after the primary completion date (PCD); PCD is the term used at ClinicalTrials.gov for the "completion date", as defined in FDAAA 801. Furthermore, this summary must be made publicly available, keeping with the Declaration of Helsinki, which makes it an ethical obligation to make the results of all medical research involving human subjects publicly available.³ As is often stated, this registry represents nowadays the most comprehensive source for information about ongoing and completed trials within and outside the USA, and we consequently chose it to conduct this research.⁴

In this work, we answered two important questions regarding the state of the evidence in radiation oncology. The first was, "Were the trials conducted in radiation oncology in compliance with the US law and therefore did they make their results publicly available?" The second was "How many of the trials conducted in radiation oncology have published their results in a peer-reviewed journal (PRJ)?" The answers to both questions are vital to our patients, to our health care system (independently of the model a country has chosen

as its own), and to the state of evidence we have within our reach as practitioners (are our treatments really based on evidence?).

METHODS

Database Search

We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015. When a PCD was missing, we instead used the completion date field. For this study and within the aforementioned date range, we considered all clinical trials that met the following criteria:

- Study type: Interventional studies
- Interventions: Radiotherapy
- Phase: Phase 3; Phase 4.

Trials with a “Withdrawn” status were excluded because these trials have ended early before enrolling the first patients.

Each trial registered on ClinicalTrials.gov has a unique identification code, “NCT”, followed by an eight-digit number. This identifier is commonly known as the NCT number. We used this NCT number to avoid trial duplicates within our final set. In order to avoid false positives, for each trial, we extracted all the information provided by ClinicalTrials.gov’s API (see Table I). We also used the Uniform Resource Locator (URL) field in order to access all the trial information registered in the database. Two researchers (JPA and PGF) independently reviewed the information displayed by using the same search protocol and decided for each trial whether the criteria mentioned above were fully met, with a

consensus discussion in case of disagreement. If they failed to reach a consensus, a third researcher (ILG) took a final decision after taking into account both arguments.

Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.

Publication Search in a PRJ

Because our query on ClinicalTrials.gov was conducted on 6 May 2016, we allowed a minimum of 24 months after the latest possible PCD (6 May 2014) for journal submission, peer review and editorial process until the trial was finally published in a PRJ. For those trials published electronically ahead of print, we used the date on which online publication occurred. Trials with a “Suspended” or “Terminated” status were excluded from this search. Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:

- The trial was published in a PRJ.
- Results reported in the publication were a primary outcome measure or a secondary outcome measure, or both.
- No abstract, poster, oral communication or private communication of a trial result was considered as a valid publication.

Each author searched PubMed, Google Scholar, and Google by using the following characteristics: NCT number, other identification numbers provided by ClinicalTrials.gov, author names, institutions, title, official title, and keywords. Matches were evaluated according to title, trial design, sample size, intervention, location, dates of recruitment and completion, study hypotheses, and primary and/or secondary outcome measures, as described in the ClinicalTrials.gov database. Matches found by each researcher were

1 always checked by a second researcher. We then categorised our data into subsets by
2 cancer subtype.
3
4

5
6 ClinicalTrials.gov also displayed publication citations at the bottom of the “Full Text View”
7 tab of a study record, under the “More Information” heading. These citations are either
8 submitted by sponsors or investigators, or are automatically indexed by ClinicalTrials.gov.
9 Citations submitted by sponsors or investigators may provide background information
10 instead of information about results. We also reviewed this linked information to evaluate
11 whether or not the information provided by sponsors or indexed by ClinicalTrials.gov was
12 relevant to our study. We applied the same methodology as explained in the previous
13 paragraph.
14
15
16
17
18
19
20
21
22
23

24
25 In order to look for publication bias, we took into account all trials with results in the
26 registry that qualified for a search in a PRJ. This set was further divided into two subsets:
27 the first contained all trials with a summary result reported in the registry and no
28 publication in a PRJ; the second contained all trials with a summary result reported in the
29 registry and a publication in a PRJ. For each subset, we further analyse positive and
30 negative result frequencies. A positive finding was defined as a result rejecting the null
31 hypothesis in favour of the experimental arm; a negative finding, on the other hand, was
32 defined as a result that either confirmed the null hypothesis or rejected it in favour of the
33 control arm.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical Analysis

We used the χ^2 test to compare publication rates in the registry between trials grouped by funding type. P values of < 0.05 were considered statistically significant. We also used the χ^2 test to compare publication rates in a PRJ between trials grouped by funding type. To test for the effect of this variable on publication, we used adjusted binary logistic regression (non-publication versus publication), which produced an odds ratio (OR) and a 95% confidence interval; an OR larger than 1.0 indicated a greater likelihood of trial publication in this group. The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American versus Other). These analyses were pre-specified and undertaken to evaluate whether or not industry funding, enrolment or country had an impact on patterns of publication. Statistical analyses were performed by using R version 3.3.1⁵

RESULTS

Overall, 490 interventional phase 3 and 4 clinical trials met the inclusion criteria. Of these 490 trials, 7 had a "Withdrawn" status and were consequently excluded. Forty-five were phase 4 trials with the remaining 438 phase 3. A total of 414 (85.7%) of all the interventional phase 3 and 4 clinical trials did not publish the compulsory summary results in the ClinicalTrials.gov registry. National Institutes of Health (NIH) funding was significantly associated with a higher likelihood of reporting results (OR 4.73, 2.77 to 8.10; $p < 0.001$). Industry funding was likewise significantly associated with a higher likelihood of reporting results in the registry (OR 3.19, 1.78 to 5.64; $p = 0.001$). No statistically significant differences were found between NIH-funded trials and Industry-funded trials (OR = 1.16, 0.62 to 2.22, $p = 0.98$) (See Table 2 and Figure 1). Although we had focus in funding as our explanatory variable we have also observed that, "being American" (in

Principal Investigator variable) was significantly associated with a lower likelihood of reporting results when adjusted by funding type and enrolment (See Table 3).

When categorised by phase, 42 (93.3%) phase 4 trials and 372 (84.9%) phase 3 trials did not publish a deposition of their results in the registry, although this percentage difference was not significant.

Overall, 387 interventional phase 3 and 4 clinical trials met the criteria for searching a publication in a PRJ (39 phase 4 trials and 348 phase 3 trials). A total of 216 (55.8%) trials each had at least one publication of their results in a PRJ, but 171 (44.2%) trials remained unpublished. NIH funding was significantly associated with a higher likelihood of published results (OR 3.73, 2.13 to 6.85; $p < 0.001$). Industry funding was not significantly associated with a higher or lower likelihood of publishing results in a peer-reviewed journal ($\chi^2 = 0.79$; $p = 0.38$) (see Table 4 and Figure 2). “Being American” was, again (with an exception for cases with NIH funding), significantly associated with a lower likelihood of published results when adjusted by funding type and enrolment. (See table 5).

Taking into account the trial phase, 24 (61.5%) phase 4 trials and 147 (42.2%) phase 3 trials remained unpublished. This difference between phase 3 and phase 4 trials was statistically significant (OR = 2.19, 1.12 to 4.40; $p = 0.02$).

Of these 387 trials, when taking into account cancer subtype, we found the following percentages for unpublished results in a PRJ (total number of unpublished trials is shown in parentheses): 37.5% for brain (12 of 32), 34.0% for breast (17 of 50), 56.3% for cervical (9 of 16), 33.3% for colorectal (7 of 21), 37.5% for endometrial (3 of 8), 100.0% for oesophagus (0 of 2), 57.1% for eye (4 of 7), 42.9% for gastric (3 of 7), 54.4% for head and neck (37 of 68), 100.0% for kidney (0 of 1), 33.3 % for leukaemia (7 of 21), 66.7% for liver (4 of 6), 46.3% for lung (19 of 41), 100.0% for melanoma (0 of 1), 100.0% for myeloma (0 of 1), 80% for metastasis (4 of 5), 30% for pancreatic (3 of 10), 43.2% for prostate (16 of

37), 55.6% for bladder (5 of 9), 33.3% for lymphoma (7 of 21), 30% for sarcoma (3 of 10), 61.5% for other (8 of 13). For those subgroups with at least 16 trials, we ran a significance test to determine whether these percentages were different from the global non-publication tendency. As can be seen in Table 6, no statistically significant difference was found in any of them.

For publication bias, only 48 trials (12.4%) met the criteria: 11 trials reported a summary result but were not published in a PRJ, and 37 trials reported a summary result and were published in a PRJ. For our first subset, 6 of 11 trials (54.5%) showed a positive finding and the remaining 5 (45.5%) a negative finding; the second subset showed a similar pattern: 19 of 37 (51.4%) had a positive finding and the remaining 18 (48.6%) a negative finding (Table 7).

DISCUSSION

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All evidence should be both published and available because withholding the results skews the evidence and therefore dangerously distorts it. When evidence is not published, those who make decisions about potential treatments do not have complete information about the outcome and the entire set of benefits and risks that a particular treatment might involve. The importance of publishing negative results has not been stressed strongly enough⁶; publishing these results not only reduces biases regarding the efficacy of a treatment, but also plays a huge role in helping science to move forward. Perhaps the most famous example of a negative result was the historic paper published by Michelson and Morley in 1883,⁷ which led a young physicist working at a patent office in Bern 22 years later, in 1905, to completely change our notion of space and time—a notion that almost one hundred years later turned out to be an essential feature in the GPS

system. This young physicist was Albert Einstein. Despite the importance of knowing whether there is publication bias in radiation oncology, the present work confirms that it is not possible to assess such bias because of a massive lack of data: a mere 15% of the trials registered at ClinicalTrials.gov had published the compulsory summary result and only 45% of all trials conducted had been published in a PRJ. Rates of publication in radiation oncology were nonetheless higher than those previously reported 3 years ago in a cross-sectional analysis of large randomised clinical trials in medicine, although comparisons are hard to make because our work is an observational study in a specific medical field with substantially different inclusion criteria.⁸

As our results showed, a large number of interventional phase 3 and 4 trials in radiation oncology have been conducted but have not published their results. Thus, 44% of all evidence collected in our field is seemingly lost forever and raises the question about the extent to which the treatments being offered to patients are really evidence based. It is worth noting that trials funded by NIH and industry showed a higher rate of reporting results in the registry than did other trials, even though nearly 70% of NIH- and industry-funded trials did not report anything in ClinicalTrials.gov. In addition, there was no statistically significant difference between trials funded by private companies or by NIH. One way to improve these reporting rates would be to apply economic sanctions against sponsors who do not comply with the regulation (such sanctions already exist in the USA by the Food and Drug Administration, although they have rarely been applied); however, economic sanctions against clinical investigators or companies might prevent them from deciding to begin a new trial if sanctions are a possibility. Having fewer trials could be damaging to the health system as a whole, as well as to future patients. A potential solution would be to institute a system whereby if clinical investigators apply for public funding, they have to disclose results of all previously conducted trials; for privately funded trials, results from all previous studies would have to be made available before the new

trial could be registered.

Recently, it has been reported that fewer than half of the trials funded by NIH were published in a PRJ.⁴ We found a far better publishing rate within the radiation oncology field, since almost 80% of all trials with NIH funding published their results in a PRJ. We found that publication rates for industry-funded trials, on the other hand, were far worse, with 50% of them remaining unpublished. An important consideration is that, leaving aside NIH-funded trials, although this 50% rate of non-publication was higher in industry-funded than in non-industry-funded trials, the differences were not statistically significant. This result is opposite to what has been sometimes reported in the medical literature.⁹

We would like also to mention that we have been surprised by the fact that, even though the law enforcing the registration and reporting of clinical trial results was an American one, American Principal Investigators were less likely to report results on ClinicalTrials.gov registry.

It is hard to fathom the reasons underlying this non-publication. One reason might be that we are living in a “publish or perish” era and most clinicians and researchers are willing to participate in a trial without questioning what is really happening with these data globally (there are more ongoing trials than ever before and, as a consequence, it is easy for investigators to participate in multiple trials at the same time; the paradox might rest on the fact that when one of those trials remain unpublished, little attention is paid to it). Another potential reason is publication bias, although it was not possible to assess it in this study. A final possibility is “the planning fallacy”^{10,11}: people tend to make terrible predictions of task completion times and what once looked like a feasible trial becomes a longer and much more difficult project to undertake. Given these possibilities, it is important to highlight initiatives such as the 2013 “Restoring Invisible and Abandoned Trials” statement, which was supported by a number of important journals, giving trialists an amnesty of 1 year to publish the results of previously unreported trials.¹²

In summary, non-publication means poor use of financial resources from funders, host institutions, and commissioning bodies. It also means loss of knowledge through hidden data, makes medical practice less evidence-based, and risks biasing the evidence in important ways. Moreover, it means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients. This ethical issue should be at the heart of our current medical practice.

REFERENCES

1. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, *et al*. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med* 2004;351:1250-1.
2. Section 801 of the Food and Drug Administration Amendments Act. SEPT. 27, 2007;121 STAT. 904 PUBLIC LAW 110–85
3. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. WMA General Assembly:1-5.
4. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2012;344:d7292
5. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
6. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. *JAMA Oncol.* 2016 Jul 1;2(7):875-81
7. A. A. Michelson and E. W. Morley. On the relative motion of the Earth and the luminiferous ether. *Am J Sci.* November 1887 Series 3 Vol. 34:333-345;

8. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013; 347:f6104
9. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A. Discontinuation and non-publication of surgical randomised controlled trials: observational study. *BMJ*. 2014 Dec 9;349:g6870
10. Kahneman D, Tversky A. Intuitive prediction: biases and corrective procedures. *TIMS Studies in Management Science*, 1979; 12,313-327.
11. Buehler R, Griffin D, Ross M. Exploring the "Planning Fallacy": Why People Underestimate Their Task Completion Times. *Journal of Personality and Social Psychology*, 1994; Vol.67. No 3. 366-381
12. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ* 2013; 346:f2865

AUTHOR'S CONTRIBUTIONS

JP-A and PG conceptualised and designed the study. JP-A and PG wrote the first draft of the manuscript. IL, EA, JP-A and PG conducted and analysed registry and peer-reviewed journal searches. AP reviewed the manuscript and helped with the interpretation of the data. All authors approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest for the present research.

FUNDING

The authors did not receive funding of any kind for this research.

Data Sharing Statement

All data used in this research are publicly available from Clinicaltrials.gov, with the inclusion criteria cited in the text.

ClinicalTrials.gov’s API Information

Information extracted			
NCT Number	Gender	Other IDs	Results First Received
Title	Age Groups	First Received	Primary Completion Date
Recruitment	Phases	Start Date	Outcome Measures
Study Results	Enrollment	Completion Date	URL
Conditions	Funded Bys	Last Updated	
Interventions	Study Types	Last Verified	
Sponsor/Collaborators	Study Designs	Acronym	

Table 1. Information extracted for each interventional Phase 3 and Phase 4 trial.

Summary of Results posted on the ClinicalTrial.gov registry

	Number of trials	Results NOT posted on ClinicalTrials.gov registry
Phase 3	438	372 (84.9 %)
Phase 4	45	42 (93.3 %)
NIH-Funded	109	74 (67.9 %)
Industry-Funded	79	56 (70.9 %)
Other-Funded	428	378 (88.31 %)
Total	483	414 (85.7 %)

Table 2. Number of trials with results not posted on ClinicalTrials.gov registry. Funded feature is not an exclusive one: trials might have been funded by a combination of the three possible options (NIH, Industry and Other).

	Being American p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p = 5.50e-5 OR 0.32, 0.18 to 0.55	p = 0.40 OR 0.99, 0.99 to 1.00
Industry-Funded	p = 6.12e-7 OR 0.24, 0.14 to 0.43	p = 0.62 OR 1.00, 0.99 to 1.00
Other-Funded	p = 4.01e-5 OR 0.23, 0.13 to 0.41	p = 0.69 OR 1.00, 0.99 to 1.00

Table 3 Adjusted binary logistic regression (non-publication versus publication in ClinicalTrials.gov) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal

	Number of trials	Results NOT published on PRJ
Phase 3	348	147 (42.2 %)
Phase 4	39	24 (61.5 %)
NIH-Funded	80	17 (21.2 %)
Industry-Funded	58	25 (43.1.9 %)
Other-Funded	344	155 (45.1 %)
Total	387	171 (44.2 %)

Table 4. Number of trials with Results not published on a PRJ. As in Table 1, the Funded feature is not exclusive, and there might be trials which were funded by a combination of the three possible options (NIH, Industry and Other).

PRJ

	Being American p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p = 0.836 OR 1.06, 0.61 to 1.84	p = 0.10 OR 1.00, 0.99 to 1.00
Industry-Funded	p = 0.006 OR 1.86, 1.20 to 2.92	p = 0.03 OR 1.00, 1.00 to 1.00
Other-Funded	p = 0.007 OR 1.84, 1.18 to 2.88	p = 0.02 OR 1.00, 1.00 to 1.00

Table 5 Adjusted binary logistic regression (non-publication versus publication in PRJ) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal by cancer subtype

	Number of tri- als	Results NOT published on PRJ	Odds Ratio (CI 95%)	p-value
Brain	32	12 (37.5%)	0.74 (0.35 – 1.559)	0.43
Breast	50	17 (34.0%)	0.61 (0.33 – 1.14)	0.12
Cervical	16	9 (56.3%)	1.66 (0.60 – 4.55)	0.32
Colorectal	21	7 (33.0%)	0.62 (0.24 – 1.561)	0.30
Endometrial	8	3 (37.5%)	-	-
Esophagus	2	0 (100%)	-	-
Eye	7	4 (57.1%)	-	-
Gastric	7	3 (42.9%)	-	-
Head&Neck	68	37 (54.4%)	1.65 (0.97 – 2.79)	0.06
Kidney	1	0 (100.0%)	-	-
Leukemia	21	7 (33.3%)	0.61 (0.24 – 1.561)	0.30
Liver	6	4 (66.6%)	-	-
Lung	41	19 (46.3.0%)	-	0.77
Melanoma	1	0 (100.0%)	-	-
Metastasis	5	4 (80.0%)	-	-
Myeloma	1	0 (100.0%)	-	-
Pancreatic	10	3 (30.0%)	-	-
Prostate	37	16 (43.2%)	0.63 (0.25 – 1.60)	0.90
Bladder	9	5 (55.5%)	-	-
Lymphoma	21	7 (33.3%)	0.62 (0.24 – 1.56)	0.90
Sarcoma	13	3 (30.0%)	-	-
Other	10	8 (61.5%)	-	-

Table 6. Number of trials with results not published in a PRJ by cancer subtype. For those subgroups with at least 16 trials we run a significant test in order to see if these percentages were different from the global non-publication tendency. For each cancer subtype odds ratio were calculated taking as reference the global set minus this cancer subtype subset.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Publication Bias Analysis

	Number of trials	Positive Results	Negative Results
Results published on PRJ	11	6 (54.5%)	5 (45.5%)
Results NOT published on PRJ	37	19 (51.4%)	18 (48.6%)
Results	48	25 (52.1%)	23 (47.9%)

Table 7. Number of trials meeting the inclusion criteria for analyzing the publication bias.

For peer review only




Figure 1 : Venn Diagram for trials in table 2




Figure 1 : Venn Diagram for trials in table 4

BMJ Open

NO PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016040.R1
Article Type:	Research
Date Submitted by the Author:	24-May-2017
Complete List of Authors:	Pérez-Alija, Jaime; Hospital Plato, Radioterapia i Oncología Gallego, Pedro; Hospital Plato, Radioterapia i Oncología Linares, Isabel; Institut Catala d' Oncologia, Radiotherapy Ambroa, Eva; Consorci Sanitari de Terrassa, Medical Physics Pedro, Agustí; Hospital Plato, Radioterapia i Oncología
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology, Health economics
Keywords:	Radiation oncology < RADIOTHERAPY, Clinical trials < THERAPEUTICS, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, medicine evidence based

SCHOLARONE™
Manuscripts

NO PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN
RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY

Jaime Pérez-Alija

Hospital Plató
C/Plató 21 08006 Barcelona, Spain

Pedro Gallego Franco *

Hospital Plató
C/Plató 21 08006 Barcelona, Spain

Isabel Linares

Institut Català d'Oncologia
Avinguda de la Granvia, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain

Eva Ambroa

Consorci Sanitari de Terrasa
Carr. Torrebonica, S/N, 08227 Terrassa, Barcelona, Spain

Agustí Pedro

Hospital Plató
C/Plató 21 08006 Barcelona, Spain

***Corresponding Author:**

Email: pedro.gallego@hospitalplato.com

Phone: 0034 666091433

FAX= 0034 934140133

POSTAL ADRESS: C/Plató 21 08006 Barcelona, Spain

KEYWORDS: Oncology, Radiation Oncology, Clinical Trials,
Health Economics, medicine evidence based

Word Count: 3124 Including Abstract and “Strengths and limitations of this Study”.

OBJECTIVES

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. We aimed to determine the rate of non-publication of interventional phase 3 and 4 clinical trials involving cancer patients undergoing radiotherapy.

SETTING

The ClinicalTrials.gov database was searched for interventional phase 3&4 trials in radiotherapy with a primary completion date before 1 January 2013. We determined how many of these registry entries have not published the compulsory deposition of their results in the database and performed a systematic search for published studies in peer-reviewed journals.

RESULTS

Of 576 trials, 484 (84.0%) did not deposit a summary result in the registry. In addition, 44.9% of them did not publish their results in a peer-reviewed journal. Similar percentages were found for most cancer subtypes: brain (41%), breast (38%), cervical (66%), colorectal (38%), lung (48%), prostate (45%), bladder (56%), head and neck (56%), lymphoma (33%).

CONCLUSIONS

Our results show that most trials in radiation oncology did not report the results in the

registry. Almost half of these trials have not been published in the biomedical literature. This means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients

Strengths and limitations of this Study

- We have considered and analyzed the higher levels of evidence-base radiation oncology.
- Each trial meeting the inclusion criteria were independently searched by at least two authors in order to assess its publication in a peer-reviewed journal.
- ClinicalTrials.gov is, by far, the largest trial registry in the world. Any applicable medical device trial or medical drug trial planned to be market on the US has to be registered in this registry.
- Insufficient statistical power and lack of data to test for hypotheses giving a plausible explanation of non-publication in radiation oncology.

BACKGROUND

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All this evidence should be both published and available, since withholding results skews the evidence and therefore dangerously distorts it. Publication of all trials conducted in radiation oncology is needed to fully determine the benefits and risks of treatments currently in use in our clinics.

Since 2005, the International Committee of Medical Journal Editors has required prospective registration of all interventional clinical studies prior to publication. It does not, however, require authors to report the results of registered trials.¹ On the other hand, a US federal law, the Food and Drug Administration Amendments Act of 2007 (FDAAA 801),² requires responsible parties of all interventional trials to submit summary results to the ClinicalTrials.gov database 12 months after the primary completion date (PCD); PCD is the term used at ClinicalTrials.gov for the "completion date", as defined in FDAAA 801. Furthermore, this summary must be made publicly available, keeping with the Declaration of Helsinki, which makes it an ethical obligation to make the results of all medical research involving human subjects publicly available.³ As is often stated, this registry represents nowadays the most comprehensive source for information about ongoing and completed trials within and outside the USA, and we consequently chose it to conduct this research.⁴

In this work, we answered two important questions regarding the state of the evidence in radiation oncology. The first was, "Were the trials conducted in radiation oncology in compliance with the US law and therefore did they make their results publicly available?" The second was "How many of the trials conducted in radiation oncology have published their results in a peer-reviewed journal (PRJ)?" The answers to both questions are vital to our patients, to our health care system (independently of the model a country has chosen

as its own), and to the state of evidence we have within our reach as practitioners (are our treatments really based on evidence?).

METHODS

Database Search

We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015. When a PCD was missing, we instead used the completion date field. We used the “Advanced Search” form to broaden our search. We filled in all the fields below as follows:

- Search Terms: “Radiotherapy” OR “Radiation Therapy” OR “Brachytherapy” OR “IMRT” OR “SBRT” OR “IMPT” OR “Radiation Oncology” [IMRT stands for Intensity-Modulated Radiation Therapy; SBRT stands for Stereotactic Body Radiation Therapy; IMPT stands for Intensity-Modulated Proton Therapy]
- Study Type: Interventional Studies
- Study Results: All Studies
- Recruitment: All Studies
- Additional Criteria → Phase: No Phase was ticked since phase 3 or 4 trials concerning radiation therapy were also registered as trials without phase.

For this study and within the aforementioned date range, we considered all clinical trials that met the following criteria:

- Study type: Interventional studies
- Interventions: Radiotherapy as standard treatment or primary focus in oncology

- Phase: Phase 3; Phase 4.

Trials with a “Withdrawn” status were excluded because these trials have ended early before enrolling the first patients.

Each trial registered on ClinicalTrials.gov has a unique identification code, “NCT”, followed by an eight-digit number. This identifier is commonly known as the NCT number. We used this NCT number to avoid trial duplicates within our final set. In order to avoid false positives, for each trial, we extracted all the information provided by ClinicalTrials.gov’s application programming interface (see Table I). We also used the Uniform Resource Locator (URL) field in order to access all the trial information registered in the database. Two researchers (JPA and PGF) independently reviewed the information displayed by using the same search protocol and decided for each trial whether the criteria mentioned above were fully met, with a consensus discussion in case of disagreement. If they failed to reach a consensus, a third researcher (ILG) took a final decision after taking into account both arguments.

Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.

Publication Search in a PRJ

Because our query on ClinicalTrials.gov was conducted on 6 May 2016, we allowed a minimum of 24 months after the latest possible PCD (6 May 2014) for journal submission, peer review and editorial process until the trial was finally published in a PRJ. For those trials published electronically ahead of print, we used the date on which online publication occurred. Trials with a “Suspended” or “Terminated” status were excluded from this search.

Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:

- The trial was published in a PRJ.
- Results reported in the publication were a primary outcome measure or a secondary outcome measure, or both.
- No abstract, poster, oral communication or private communication of a trial result was considered as a valid publication.

Each author searched PubMed, Google Scholar, and Google by using the following characteristics: NCT number, other identification numbers provided by ClinicalTrials.gov, author names, institutions, title, official title, and keywords. Matches were evaluated according to title, trial design, sample size, intervention, location, dates of recruitment and completion, study hypotheses, and primary and/or secondary outcome measures, as described in the ClinicalTrials.gov database. Matches found by each researcher were always checked by a second researcher. We then categorised our data into subsets by cancer subtype.

ClinicalTrials.gov also displayed publication citations at the bottom of the “Full Text View” tab of a study record, under the “More Information” heading. These citations are either submitted by sponsors or investigators, or are automatically indexed by ClinicalTrials.gov. Citations submitted by sponsors or investigators may provide background information instead of information about results. We also reviewed this linked information to evaluate whether or not the information provided by sponsors or indexed by ClinicalTrials.gov was relevant to our study. We applied the same methodology as explained in the previous paragraph.

In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ. This set was further divided into two subsets: the first contained all trials with a summary result reported in the registry and no publication in a PRJ; the second contained all trials with a summary result reported in the

registry and a publication in a PRJ. For each subset, we further analyse positive and negative result frequencies. A positive finding was defined as a result rejecting the null hypothesis in favour of the experimental arm; a negative finding, on the other hand, was defined as a result that either confirmed the null hypothesis or rejected it in favour of the control arm.

Statistical Analysis

We used the χ^2 test to compare publication rates in the registry between trials grouped by funding type. P values of < 0.05 were considered statistically significant. We also used the χ^2 test to compare publication rates in a PRJ between trials grouped by funding type. To test for the effect of this variable on publication, we used adjusted binary logistic regression (non-publication versus publication), which produced an odds ratio (OR) and a 95% confidence interval; an OR larger than 1.0 indicated a greater likelihood of trial publication in this group. The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other). These analyses was pre-specified and undertaken to evaluate whether or not industry funding, enrolment or country had an impact on patterns of publication. Statistical analyses were performed by using R version 3.3.1⁵

RESULTS

Overall, 583 interventional phase 3 and 4 clinical trials met the inclusion criteria. Of these 583 trials, 7 had a “Withdrawn” status and were consequently excluded. Fifty-one were phase 4 trials with the remaining 525 phase 3. A total of 484 (84.0%) of all the interventional phase 3 and 4 clinical trials did not publish the compulsory summary results in the ClinicalTrials.gov registry. National Institutes of Health (NIH) funding was significantly associated with a higher likelihood of reporting results (OR 3.23, 1.89 to 5.57; $p < 0.001$). Industry funding was likewise significantly associated with a higher likelihood of reporting results in the registry (OR 3.43, 1.93 to 6.08; $p < 0.001$). No statistically significant differences were found between NIH-funded trials and Industry-funded trials (OR = 1.14, 0.64 to 2.04, $p = 0.66$) (See Table 2 and Figure 1). Although we had focus in funding as our explanatory variable we have also observed that, “being American” (in Principal Investigator variable) was significantly associated with a higher likelihood of reporting results when adjusted by funding type and enrolment (See Table 3).

When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry, although this percentage difference was not significant (OR 1.75, 0.68 to 5.99; $p = 0.301$)

Overall, 463 interventional phase 3 and 4 clinical trials met the criteria for searching a publication in a PRJ (43 phase 4 trials and 420 phase 3 trials). A total of 255 (55.1%) trials each had at least one publication of their results in a PRJ, but 208 (44.9%) trials remained unpublished. NIH funding was significantly associated with a higher likelihood of published results (OR 3.17, 1.85 to 5.55; $p < 0.001$). Industry funding was not significantly associated with a higher or lower likelihood of publishing results in a peer-reviewed journal (OR 1.14, 0.67 to 1.98; $p = 0.63$) (see Table 4 and Figure 2). “Being American” was not significantly associated with a lower or higher likelihood of publishing results when adjusted by funding type and enrolment. (See table 5).

Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished. This difference between phase 3 and phase 4 trials was statistically significant (OR = 2.23, 1.18 to 4.34; $p = 0.02$).

Of these 463 trials, when taking into account cancer subtype, we found the following percentages for unpublished results in a PRJ (total number of unpublished trials is shown in parentheses): 41.2% for brain (14 of 34), 37.9% for breast (25 of 66), 61.1% for cervical (11 of 18), 37.9% for colorectal (11 of 29), 33.3% for endometrial (3 of 9), 75% for oesophagus (3 of 4), 62.5% for eye (5 of 8), 37.5% for gastric (3 of 8), 55.6% for head and neck (47 of 84), 100.0% for kidney (2 of 2), 36.0% for leukaemia (9 of 25), 50.0% for liver (4 of 8), 48.1% for lung (25 of 52), 100.0% for melanoma (1 of 1), 66.7% for myeloma (2 of 3), 80% for metastasis (4 of 5), 36.4% for pancreatic (4 of 11), 45.2% for prostate (19 of 42), 55.6% for bladder (5 of 9), 33.3% for lymphoma (7 of 21), 33.3% for sarcoma (4 of 12), 61.5% for other (8 of 13). For all subgroups we ran a significance test to determine whether these percentages were different from the global non-publication tendency. As can be seen in Table 6, no statistically significant difference was found in any of them with the exception of head and neck which showed slightly worse numbers

For publication bias, only 67 trials (14.4%) met the criteria: 18 trials reported a summary result but were not published in a PRJ, and 49 trials reported a summary result and were published in a PRJ. For our first subset, 8 of 18 trials (44.4%) showed a positive finding and the remaining 10 (55.6%) a negative finding; the second subset showed a similar pattern: 24 of 49 (49.0%) had a positive finding and the remaining 25 (51%) a negative finding (Table 7).

DISCUSSION

Clinical trials produce the best data available for decision-making in modern evidence-

based medicine. All evidence should be both published and available because withholding the results skews the evidence and therefore dangerously distorts it. When evidence is not published, those who make decisions about potential treatments do not have complete information about the outcome and the entire set of benefits and risks that a particular treatment might involve. The importance of publishing negative results has not been stressed strongly enough⁶; publishing these results not only reduces biases regarding the efficacy of a treatment, but also plays a huge role in helping science to move forward. Perhaps the most famous example of a negative result was the historic paper published by Michelson and Morley in 1883,⁷ which led a young physicist working at a patent office in Bern 22 years later, in 1905, to completely change our notion of space and time—a notion that almost one hundred years later turned out to be an essential feature in the GPS system. This young physicist was Albert Einstein. Despite the importance of knowing whether there is publication bias in radiation oncology, the present work confirms that it is not possible to assess such bias because of a massive lack of data: a mere 15% of the trials registered at ClinicalTrials.gov had published the compulsory summary result and only 45% of all trials conducted had been published in a PRJ. Rates of publication in radiation oncology were nonetheless higher than those previously reported 3 years ago in a cross-sectional analysis of large randomised clinical trials in medicine, although comparisons are hard to make because our work is an observational study in a specific medical field with substantially different inclusion criteria.⁸

As our results showed, a large number of interventional phase 3 and 4 trials in radiation oncology have been conducted but have not published their results. Thus, 45% of all evidence collected in our field is seemingly lost forever and raises the question about the extent to which the treatments being offered to patients are really evidence based. It is worth noting that trials funded by NIH and industry showed a higher rate of reporting results in the registry than did other trials, even though nearly 65% of NIH- and industry-

1 funded trials did not report anything in ClinicalTrials.gov. In addition, there was no
2 statistically significant difference between trials funded by private companies or by NIH.
3 One way to improve these reporting rates would be to apply economic sanctions against
4 sponsors who do not comply with the regulation (such sanctions already exist in the USA
5 by the Food and Drug Administration, although they have rarely been applied); however,
6 economic sanctions against clinical investigators or companies might prevent them from
7 deciding to begin a new trial if sanctions are a possibility. Having fewer trials could be
8 damaging to the health system as a whole, as well as to future patients. A potential
9 solution would be to institute a system whereby if clinical investigators apply for public
10 funding, they have to disclose results of all previously conducted trials; for privately funded
11 trials, results from all previous studies would have to be made available before the new
12 trial could be registered.

13 Recently, it has been reported that fewer than half of the trials funded by NIH were
14 published in a PRJ.⁴ We found a far better publishing rate within the radiation oncology
15 field, since almost 75% of all trials with NIH funding published their results in a PRJ. We
16 found that publication rates for industry-funded trials, on the other hand, were far worse,
17 with 60% of them remaining unpublished. An important consideration is that, leaving aside
18 NIH-funded trials, although this 50% rate of non-publication was higher in industry-funded
19 than in non-industry-funded trials, the differences were not statistically significant. This
20 result is opposite to what has been sometimes reported in the medical literature.⁹

21 We would like also to mention that American Principal Investigators were more likely to
22 report results on ClinicalTrials.gov registry and this might be because the law enforcing the
23 registration and reporting of clinical trial results was an American one.

24 It is hard to fathom the reasons underlying this non-publication. One reason might be that
25 we are living in a “publish or perish” era and most clinicians and researchers are willing to
26 participate in a trial without questioning what is really happening with these data globally

(there are more ongoing trials than ever before and, as a consequence, it is easy for investigators to participate in multiple trials at the same time; the paradox might rest on the fact that when one of those trials remain unpublished, little attention is paid to it). Another potential reason is publication bias, although it was not possible to assess it in this study. A final possibility is “the planning fallacy”^{10,11}: people tend to make terrible predictions of task completion times and what once looked like a feasible trial becomes a longer and much more difficult project to undertake. Given these possibilities, it is important to highlight initiatives such as the 2013 “Restoring Invisible and Abandoned Trials” statement, which was supported by a number of important journals, giving trialists an amnesty of 1 year to publish the results of previously unreported trials.¹²

As it has been previously stated in the Background section we chose ClinicalTrial.gov registry because this registry represented the most comprehensive source for information about ongoing and completed trials within and outside the USA. However, as large and important as this registry is, many trials conducted in radiotherapy have been registered in other registries. Therefore, it should be taken into account that our dataset did not represent the entire population of interventional phase 3 and 4 trials conducted in radiotherapy. On the other hand, we assumed most phases 3 and 4 trials conducted in radiotherapy would be willing to apply their results on the USA soil and therefore have to comply with the FDAAA 801.

There was also a limitation of our search method due to a limitation of the ClinicalTrials.gov search engine. Although search results displayed by the registry depend on the selection of words made, radiotherapy trials were not uniquely identified by the term “radiotherapy”. When using only “radiotherapy” in the search box, we discovered a high percentage of false positive results. The same was true when using other search terms as “Radiation Therapy” or “Radiation Oncology”. In order to account for this we had to double-check manually every result display in the search result. We performed multiple searches

with different search terms in order to register as many as possible radiotherapy trials, but some of them might have slipped our search method even if they were registered in ClinicalTrials.gov.

In summary, non-publication means poor use of financial resources from funders, host institutions, and commissioning bodies. It also means loss of knowledge through hidden data, makes medical practice less evidence-based, and risks biasing the evidence in important ways. Moreover, it means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients. This ethical issue should be at the heart of our current medical practice.

REFERENCES

1. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, *et al*. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med* 2004;351:1250-1.
2. Section 801 of the Food and Drug Administration Amendments Act. SEPT. 27, 2007;121 STAT. 904 PUBLIC LAW 110-85
3. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. WMA General Assembly:1-5.
4. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2012;344:d7292
5. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
6. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. *JAMA Oncol*.

2016 Jul 1;2(7):875-81

7. A. A. Michelson and E. W. Morley. On the relative motion of the Earth and the luminiferous ether. *Am J Sci.* November 1887 Series 3 Vol. 34:333-345;

8. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013; 347:f6104

9. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A. Discontinuation and non-publication of surgical randomised controlled trials: observational study. *BMJ.* 2014 Dec 9;349:g6870

10. Kahneman D, Tversky A. Intuitive prediction: biases and corrective procedures. *TIMS Studies in Management Science*, 1979; 12,313-327.

11. Buehler R, Griffin D, Ross M. Exploring the “Planning Fallacy”: Why People Underestimate Their Task Completion Times. *Journal of Personality and Social Psychology*, 1994; Vol.67. No 3. 366-381

12. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ* 2013; 346:f2865

AUTHOR’S CONTRIBUTIONS

JP-A and PG conceptualised and designed the study. JP-A and PG wrote the first draft of the manuscript. IL, EA, JP-A and PG conducted and analysed registry and peer-reviewed journal searches. AP reviewed the manuscript and helped with the interpretation of the data. All authors approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest for the present research.

FUNDING

The authors did not receive funding of any kind for this research.

Data Sharing Statement

All data used in this research are publicly available from Clinicaltrials.gov, with the inclusion criteria cited in the text.

ClinicalTrials.gov's API Information

Information extracted			
NCT Number	Gender	Other IDs	Results First Received
Title	Age Groups	First Received	Primary Completion Date
Recruitment	Phases	Start Date	Outcome Measures
Study Results	Enrollment	Completion Date	URL
Conditions	Funded Bys	Last Updated	
Interventions	Study Types	Last Verified	
Sponsor/Collaborators	Study Designs	Acronym	

Table 1. Information extracted for each interventional Phase 3 and Phase 4 trial.

Summary of Results posted on the ClinicalTrial.gov registry

	Number of trials	Results NOT posted on ClinicalTrials.gov registry
Phase 3	525	438 (83.4 %)
Phase 4	51	46 (90.2 %)
NIH-Funded	146	93 (63.7 %)
Industry-Funded	85	56 (65.9 %)
Other-Funded	502	450 (89.6 %)
Total	576	484 (84.0 %)

Table 2. Number of trials with results not posted on ClinicalTrials.gov registry. Funded feature is not an exclusive one: trials might have been funded by a combination of the three possible options (NIH, Industry and Other).

	Being American p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p = 5.72e-6 OR 3.54, 2.06 to 6.16	p = 0.011 OR 1.00, 1.00 to 1.00
Industry-Funded	p = 1.52e-12 OR 5.98, 3.68 to 9.94	p = 0.06 OR 1.00, 0.99 to 1.00
Other-Funded	p = 2.22e-12 OR 6.70, 3.99 to 11.58	p = 0.27 OR 1.00, 0.99 to 1.00

Table 3 Adjusted binary logistic regression (non-publication versus publication in ClinicalTrials.gov) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal

	Number of trials	Results NOT published on PRJ
Phase 3	420	181 (43.1 %)
Phase 4	43	27 (62.8 %)
NIH-Funded	113	30 (26.5 %)
Industry-Funded	64	26 (40.6 %)
Other-Funded	412	189 (45.9%)
Total	463	208 (44.9%)

Table 4. Number of trials with Results not published on a PRJ. As in Table 1, the Funded feature is not exclusive, and there might be trials which were funded by a combination of the three possible options (NIH, Industry and Other).

PRJ

	Being American p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p = 0.691 OR 0.91, 0.56 to 1.46	p = 0.07 OR 1.00, 0.99 to 1.00
Industry-Funded	p = 0.052 OR 1.50, 1.00 to 2.26	p = 0.087 OR 1.00, 0.99 to 1.00
Other-Funded	p = 0.054 OR 1.49, 0.99 to 2.25	p = 0.117 OR 1.00, 0.99 to 1.00

Table 5 Adjusted binary logistic regression (non-publication versus publication in PRJ) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal by cancer subtype

	Number of tri- als	Results NOT published on PRJ	Odds Ratio (CI 95%)	p-value
Brain	34	14 (41.2%)	0.85 (0.42 to 1..72)	0.65
Breast	66	25 (37.9%)	0.71 (0.42 to 1.22)	0.21
Cervical	18	11 (61.1%)	1.98 (0.75 to 5.20)	0.16
Colorectal	29	11 (37.9%)	0.74 (0.34 to 1.59)	0.43
Endometrial	9	3 (33.3%)	0.61 (0.15 to 2.46)	0.48
Esophagus	4	3 (75%)	3.72 (0.38 to 36)	0.22
Eye	8	5 (62.5%)	2.07 (0.49 to 8.76)	0.31
Gastric	8	3 (37.5%)	0.73 (0.17 to 3.10)	0.67
Head&Neck	84	47 (55.6%)	1.72 (1.07 to 2.77)	0.03
Kidney	2	2 (100.0%)	NaN	0.12
Leukemia	25	9 (36.0%)	0.68 (0.29 to 1.56)	0.36
Liver	8	4 (50.0%)	1.23 (0.30 to 4.98)	0.77
Lung	52	25 (48.1%)	1.15 (0.65 to 2.06)	0.63
Melanoma	1	1 (100.0%)	NaN	0.27
Metastasis	5	4 (80.0%)	4.98 (0.55 to 44.9)	0.11
Myeloma	3	2 (66.7%)	2.47 (0.22 to 27.39)	0.44
Pancreatic	11	4 (36.4%)	0.69 (0.20 to 2.41)	0.56
Prostate	42	19 (45.2%)	1.01 (0.54 to 1.92)	0.97
Bladder	9	5 (55.5%)	1.55 (0.41 to 5.83)	0.52
Lymphoma	21	7 (33.3%)	0.60 (0.24 to 1.51)	0.27
Sarcoma	12	4 (33.3%)	0.61 (0.18 to 2.04)	0.41
Other	13	8 (61.5%)	2 (0.64 to 6.21)	0.22

Table 6. Number of trials with results not published in a PRJ by cancer subtype. For those subgroups with at

least 16 trials we run a significant test in order to see if these percentages were different from the global non-publication tendency. For each cancer subtype odds ratio were calculated taking as reference the global set minus this cancer subtype subset.

Publication Bias Analysis

	Number of trials	Positive Results	Negative Results
Results published on PRJ	18	8 (44.4%)	10 (55.6%)
Results NOT published on PRJ	49	24 (49.0%)	25 (51%)
Results	67	32 (47.8%)	35 (52.2%)

Table 7. Number of trials meeting the inclusion criteria for analyzing the publication bias.

Figure legends

Figure 1 : Distribution of trials in table 2

Figure 2 : Distribution of trials in table 4




Figure 1 : Distribution of trials in table 2
705x478mm (72 x 72 DPI)




Figure 2 : Distribution of trials in table 4

705x478mm (72 x 72 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	<p>(a) Indicate the study’s design with a commonly used term in the title or the abstract</p> <p>NO PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY</p>
		<p>(b) Provide in the abstract an informative and balanced summary of what was done and what was found.</p> <p>Page 2.</p>
Introduction		
Background/rationale	2	<p>Explain the scientific background and rationale for the investigation being reported</p> <p>Page 4: Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All this evidence should be both published and available, since withholding results skews the evidence and therefore dangerously distorts it. Publication of all trials conducted in radiation oncology is needed to fully determine the benefits and risks of treatments currently in use in our clinics.</p>
Objectives	3	<p>State specific objectives, including any prespecified hypotheses</p> <p>Page 4: In this work, we answered two important questions regarding the state of the evidence in radiation oncology. The first was, “Were the trials conducted in radiation oncology in compliance with the US law and therefore did they make their results publicly available?” The second was “How many of the trials conducted in radiation oncology have published their results in a peer-reviewed journal (PRJ)?” The answers to both questions are vital to our patients, to our health care system (independently of the model a country has chosen as its own), and to the state of evidence we have within our reach as practitioners (are our treatments really based on evidence?).</p>
Methods		
Study design	4	<p>Present key elements of study design early in the paper</p> <p>Page 5: the key elements of the study are presented: The detailed search in the ClinicaTrials.gov database, and the criteria to classify the trials.</p>
Setting	5	<p>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</p> <p>This item is not directly applicable to our study. However, if we understand participants as trials, the relevant dates and settings are described in Page 5-8:</p> <p>We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015.</p> <p>Because our query on ClinicalTrials.gov was conducted on 6 May 2016, we allowed a minimum of 24 months after the latest possible PCD (6 May 2014) for journal submission, peer review and editorial process until the trial was finally published in a PRJ.</p>

Participants	6	<p>(a) Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>Page 5-6: For this study and within the aforementioned date range, we considered all clinical trials that met the following criteria:</p> <ul style="list-style-type: none"> • Study type: Interventional studies • Interventions: Radiotherapy as standard treatment or primary focus in oncology • Phase: Phase 3; Phase 4. <p>Trials with a “Withdrawn” status were excluded because these trials have ended early before enrolling the first patients.</p>
Variables	7	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</p> <p>Page 6 : Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.</p> <p>Page 7 : Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:</p> <ul style="list-style-type: none"> • The trial was published in a PRJ. <p>Page 8 : In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ.</p>
Data sources/ measurement	8*	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p> <p>Page 5 : We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015. When a PCD was missing, we instead used the completion date field. We used the “Advanced Search” form to broaden our search. We filled in all the fields below as follows:</p> <ul style="list-style-type: none"> • Search Terms: “Radiotherapy” OR “Radiation Therapy” OR “Brachytherapy” OR “IMRT” OR “SBRT” OR “IMPT” OR “Radiation Oncology” [IMRT stands for Intensity-Modulated Radiation Therapy; SBRT stands for Stereotactic Body Radiation Therapy; IMPT stands for Intensity-Modulated Proton Therapy] • Study Type: Interventional Studies • Study Results: All Studies • Recruitment: All Studies • Additional Criteria → Phase: No Phase was ticked since phase 3 or 4 trials concerning radiation therapy were also registered as trials without phase.

Bias

9 Describe any efforts to address potential sources of bias

Page 7: Each author searched PubMed, Google Scholar, and Google by using the following characteristics: NCT number, other identification numbers provided by ClinicalTrials.gov, author names, institutions, title, official title, and keywords. Matches were evaluated according to title, trial design, sample size, intervention, location, dates of recruitment and completion, study hypotheses, and primary and/or secondary outcome measures, as described in the ClinicalTrials.gov database. Matches found by each researcher were always checked by a second researcher. We then categorised our data into subsets by cancer subtype.

Study size 10 Explain how the study size was arrived at

This item is not directly applicable to our study

Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why

Page 6: Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.

Page 7: Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:

- The trial was published in a PRJ.

Page 8: In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ. This set was further divided into two subsets: the first contained all trials with a summary result reported in the registry and no publication in a PRJ; the second contained all trials with a summary result reported in the registry and a publication in a PRJ. For each subset, we further analyse positive and negative result frequencies. A positive finding was defined as a result rejecting the null hypothesis in favour of the experimental arm; a negative finding, on the other hand, was defined as a result that either confirmed the null hypothesis or rejected it in favour of the control arm.

Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses

Page 8-9:

We used the χ^2 test to compare publication rates in the registry between trials grouped by funding type. P values of < 0.05 were considered statistically significant. We also used the χ^2 test to compare publication rates in a PRJ between trials grouped by funding type. To test for the effect of this variable on publication, we used adjusted binary logistic regression (non-publication versus publication), which produced an odds ratio (OR) and a 95% confidence interval; an OR larger than 1.0 indicated a greater likelihood of trial publication in this group. The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other). These analyses was pre-specified and undertaken to evaluate whether or not industry funding, enrolment or country had an impact on patterns of publication. Statistical analyses were performed

by using R version 3.3.1⁵

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>Page 9: Overall, 583 interventional phase 3 and 4 clinical trials met the inclusion criteria. Of these 583 trials.... Fifty-one were phase 4 trials with the remaining 525 phase 3... Overall, 463 interventional phase 3 and 4 clinical trials met the criteria for searching a publication in a PRJ (43 phase 4 trials and 420 phase 3 trials)... Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished...</p> <p>(b) Give reasons for non-participation at each stage</p> <p>Not applicable</p> <p>(c) Consider use of a flow diagram</p> <p>We have addressed two Venn's diagrams to clarify the trials categories.</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>Not applicable</p> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Not applicable</p>
Outcome data	15*	<p>Report numbers of outcome events or summary measures</p> <p>Page 9 :</p> <p>Fifty-one were phase 4 trials with the remaining 525 phase 3. A total of 484 (84.0%) of all the interventional phase 3 and 4 clinical trials did not publish the compulsory summary results in the ClinicalTrials.gov registry</p> <p>When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry,</p> <p>Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished.</p> <p>Of these 463 trials, when taking into account cancer subtype, we found the following percentages for unpublished results in a PRJ (total number of unpublished trials is shown in parentheses): 41.2% for brain...</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Page 8: The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other).</p> <p>Page 9: National Institutes of Health (NIH) funding was significantly associated with a higher likelihood of reporting results (OR 3.23, 1.89 to 5.57; $p < 0.001$).</p>

Industry funding was likewise significantly associated with a higher likelihood of reporting results in the registry (OR 3.43, 1.93 to 6.08; $p < 0.001$). No statistically significant differences were found between NIH-funded trials and Industry-funded trials (OR = 1.14, 0.64 to 2.04, $p = 0.66$)

When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry, although this percentage difference was not significant (OR 1.75, 0.68 to 5.99; $p = 0.301$)

NIH funding was significantly associated with a higher likelihood of published results (OR 3.17, 1.85 to 5.55; $p < 0.001$). Industry funding was not significantly associated with a higher or lower likelihood of publishing results in a peer-reviewed journal (OR 1.14, 0.67 to 1.98; $p = 0.63$) (see Table 4 and Figure 2). “Being American” was not significantly associated with a lower or higher likelihood of published results when adjusted by funding type and enrolment. (See table 5).

<hr/>		
(b) Report category boundaries when continuous variables were categorized		
Not applicable		
<hr/>		
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		
Not applicable		
<hr/>		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
 Page 10: For publication bias, only 67 trials (14.4%) met the criteria: 18 trials reported a summary result but were not published in a PRJ, and 49 trials reported a summary result and were published in a PRJ. For our first subset, 8 of 18 trials (44.4%) showed a positive finding and the remaining 10 (55.6%) a negative finding; the second subset showed a similar pattern: 24 of 49 (49.0%) had a positive finding and the remaining 25 (51%) a negative finding (Table 7).		
<hr/>		
Discussion		
Key results	18	Summarise key results with reference to study objectives
 Page 11: Despite the importance of knowing whether there is publication bias in radiation oncology, the present work confirms that it is not possible to assess such bias because of a massive lack of data: a mere 15% of the trials registered at ClinicalTrials.gov had published the compulsory summary result and only 45% of all trials conducted had been published in a PRJ.		
<hr/>		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
 Page 13-14: As it has been previously stated in the Background section we chose ClinicalTrials.gov registry because this registry represented the most comprehensive source for information about ongoing and completed trials within and outside the USA. However, as large and important as this registry is, many trials conducted in radiotherapy have been registered in other registries. Therefore, it should be taken into account that our dataset did not represent the entire population of interventional phase 3 and 4 trials conducted in radiotherapy. On the other hand, we assumed most phases 3 and 4 trials conducted in radiotherapy would be willing to apply their results on the USA soil and therefore have to comply with the FDAAA 801, There was also a limitation of our search method due to a limitation of the		

ClinicalTrials.gov search engine. Although search results displayed by the registry depend on the selection of words made, radiotherapy trials were not uniquely identified by the term “radiotherapy”. When using only “radiotherapy” in the search box, we discovered a high percentage of false positive results. The same was true when using other search terms as “Radiation Therapy” or “Radiation Oncology”. In order to account for this we had to double-check manually every result display in the search result. We performed multiple searches with different search terms in order to register as many as possible radiotherapy trials, but some of them might have slipped our search method even if they were registered in ClinicalTrials.gov.

Interpretation	20	<p>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</p> <p>Page 14: In summary, non-publication means poor use of financial resources from funders, host institutions, and commissioning bodies. It also means loss of knowledge through hidden data, makes medical practice less evidence-based, and risks biasing the evidence in important ways. Moreover, it means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients. This ethical issue should be at the heart of our current medical practice.</p>
Generalisability	21	<p>Discuss the generalisability (external validity) of the study results</p> <p>Pages 11-12: Rates of publication in radiation oncology were nonetheless higher than those previously reported 3 years ago in a cross-sectional analysis of large randomised clinical trials in medicine, although comparisons are hard to make because our work is an observational study in a specific medical field with substantially different inclusion criteria.⁸</p>
Other information		
Funding	22	<p>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</p> <p>Not applicable.</p>

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016040.R2
Article Type:	Research
Date Submitted by the Author:	13-Jul-2017
Complete List of Authors:	Pérez-Alija, Jaime; Hospital Plato, Radioterapia i Oncología Gallego, Pedro; Hospital Plato, Radioterapia i Oncología Linares, Isabel; Institut Catala d' Oncologia, Radiotherapy Ambroa, Eva; Consorci Sanitari de Terrassa, Medical Physics Pedro, Agustí; Hospital Plato, Radioterapia i Oncología
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology, Health economics
Keywords:	Radiation oncology < RADIOTHERAPY, Clinical trials < THERAPEUTICS, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, medicine evidence based

SCHOLARONE™
Manuscripts

**PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN
RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY**

Jaime Pérez-Alija

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

Pedro Gallego Franco *

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

Isabel Linares

Institut Català d'Oncologia

Avinguda de la Granvia, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain

Eva Ambroa

Consorci Sanitari de Terrasa

Carr. Torrebonica, S/N, 08227 Terrassa, Barcelona, Spain

Agustí Pedro

Hospital Plató

C/Plató 21 08006 Barcelona, Spain

***Corresponding Author:**

Email: pedro.gallego@hospitalplato.com

Phone: 0034 666091433

FAX= 0034 934140133

POSTAL ADRESS: C/Plató 21 08006 Barcelona, Spain

KEYWORDS: Oncology, Radiation Oncology, Clinical Trials,

Health Economics, medicine evidence based

Word Count: 3124 Including Abstract and “Strengths and limitations of this Study”.

OBJECTIVES

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. We aimed to determine the rate of non-publication of interventional phase 3 and 4 clinical trials involving cancer patients undergoing radiotherapy.

SETTING

The ClinicalTrials.gov database was searched for interventional phase 3&4 trials in radiotherapy with a primary completion date before 1 January 2013. We determined how many of these registry entries have not published the compulsory deposition of their results in the database and performed a systematic search for published studies in peer-reviewed journals.

RESULTS

Of 576 trials, 484 (84.0%) did not deposit a summary result in the registry. In addition, 44.9% of them did not publish their results in a peer-reviewed journal. Similar percentages were found for most cancer subtypes: brain (41%), breast (38%), cervical (66%), colorectal (38%), lung (48%), prostate (45%), bladder (56%), head and neck (56%), lymphoma (33%).

CONCLUSIONS

Our results show that most trials in radiation oncology did not report the results in the

registry. Almost half of these trials have not been published in the biomedical literature. This means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients

Strengths and limitations of this Study

- We have considered and analyzed the higher levels of evidence-base radiation oncology.
- Each trial meeting the inclusion criteria were independently searched by at least two authors in order to assess its publication in a peer-reviewed journal.
- ClinicalTrials.gov is, by far, the largest trial registry in the world. Any applicable medical device trial or medical drug trial planned to be market on the US has to be registered in this registry.
- Insufficient statistical power and lack of data to test for hypotheses giving a plausible explanation of non-publication in radiation oncology.

BACKGROUND

Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All this evidence should be both published and available, since withholding results skews the evidence and therefore dangerously distorts it. Publication of all trials conducted in radiation oncology is needed to fully determine the benefits and risks of treatments currently in use in our clinics.

Since 2005, the International Committee of Medical Journal Editors has required prospective registration of all interventional clinical studies prior to publication. It does not, however, require authors to report the results of registered trials.¹ On the other hand, a US federal law, the Food and Drug Administration Amendments Act of 2007 (FDAAA 801),² requires responsible parties of all interventional trials to submit summary results to the ClinicalTrials.gov database 12 months after the primary completion date (PCD); PCD is the term used at ClinicalTrials.gov for the "completion date", as defined in FDAAA 801. Furthermore, this summary must be made publicly available, keeping with the Declaration of Helsinki, which makes it an ethical obligation to make the results of all medical research involving human subjects publicly available.³

In this work, we answered two important questions regarding the state of the evidence in radiation oncology. The first was, "Were the trials conducted in radiation oncology in compliance with the US law and therefore did they make their results publicly available?" The second was "How many of the trials conducted in radiation oncology have published their results in a peer-reviewed journal (PRJ)?" The answers to both questions are vital to our patients, to our health care system (independently of the model a country has chosen as its own), and to the state of evidence we have within our reach as practitioners (are our treatments really based on evidence?).

METHODS

Data source

ClinicalTrials.gov is a clinical trial registry and results database that provides the public with access to registrations and summary results information for clinical studies. This registry is maintained by the National Library of Medicine at the National Institutes of Health (NIH). As is often stated, this registry represents nowadays the most comprehensive source for information about ongoing and completed trials within and outside the USA, and we consequently chose it to conduct this research.⁴

Database Search

We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015. We chose this date because we had to allow a minimum 12 month period for publication of the compulsory summary results in the registry (16 months in our case). When a PCD was missing, we instead used the completion date field. We used the “Advanced Search” form to broaden our search (Box 1).

Box 1 : Search Terms in Clinical Trial Registry

- Search Terms: “Radiotherapy” OR “Radiation Therapy” OR “Brachytherapy” OR “IMRT” OR “SBRT” OR “IMPT” OR “Radiation Oncology” [IMRT stands for Intensity-Modulated Radiation Therapy; SBRT stands for Stereotactic Body Radiation Therapy; IMPT stands for Intensity-Modulated Proton Therapy]
- Study Type: Interventional Studies
- Study Results: All Studies
- Recruitment: All Studies
- Additional Criteria → Phase: No Phase was ticked since phase 3 or 4 trials concerning radiation therapy were also registered as trials without phase.

For this study and within the aforementioned date range, we considered all clinical trials that met the criteria showed in Box 2.

Box 2 : Search Terms in Clinical Trial Registry II

- Study type: Interventional studies
- Interventions: Radiotherapy as standard treatment or primary focus in oncology
- Phase: Phase 3; Phase 4.

Trials with a “Withdrawn” status were excluded because these trials have ended early before enrolling the first patients.

Each trial registered on ClinicalTrials.gov has a unique identification code, “NCT”, followed by an eight-digit number. This identifier is commonly known as the NCT number. We used

this NCT number to avoid trial duplicates within our final set. In order to avoid false positives, for each trial, we extracted all the information provided by ClinicalTrials.gov’s application programming interface (see Table I). We also used the Uniform Resource Locator (URL) field in order to access all the trial information registered in the database. Two researchers (JPA and PGF) independently reviewed the information displayed by using the same search protocol and decided for each trial whether the criteria mentioned above were fully met, with a consensus discussion in case of disagreement. If they failed to reach a consensus, a third researcher (ILG) took a final decision after taking into account both arguments.

Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag. (See Figure 1)

Publication Search in a PRJ

Because our query on ClinicalTrials.gov was conducted on 6 May 2016, we allowed a minimum of 24 months after the latest possible PCD (6 May 2014) for journal submission, peer review and editorial process until the trial was finally published in a PRJ. For those trials published electronically ahead of print, we used the date on which online publication occurred. Trials with a “Suspended” or “Terminated” status were excluded from this search (See Figure 2).

Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the criteria showed in Box 3.

Box 3 : Criteria listed for PRJ Search

- The trial was published in a PRJ.
- Results reported in the publication were a primary outcome measure or a secondary outcome measure, or both.
- No abstract, poster, oral communication or private communication of a trial result was considered as a valid publication.

Each author searched PubMed, Google Scholar, and Google by using the following characteristics: NCT number, other identification numbers provided by ClinicalTrials.gov, author names, institutions, title, official title, and keywords. Matches were evaluated according to title, trial design, sample size, intervention, location, dates of recruitment and completion, study hypotheses, and primary and/or secondary outcome measures, as described in the ClinicalTrials.gov database. Matches found by each researcher were always checked by a second researcher. We then categorised our data into subsets by cancer subtype.

ClinicalTrials.gov also displayed publication citations at the bottom of the “Full Text View” tab of a study record, under the “More Information” heading. These citations are either submitted by sponsors or investigators, or are automatically indexed by ClinicalTrials.gov. Citations submitted by sponsors or investigators may provide background information instead of information about results. We also reviewed this linked information to evaluate whether or not the information provided by sponsors or indexed by ClinicalTrials.gov was relevant to our study. We applied the same methodology as explained in the previous paragraph.

In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ. This set was further divided into two subsets: the first contained all trials with a summary result reported in the registry and no publication in a PRJ; the second contained all trials with a summary result reported in the registry and a publication in a PRJ. For each subset, we further analyse positive and negative result frequencies. A positive finding was defined as a result rejecting the null hypothesis in favour of the experimental arm; a negative finding, on the other hand, was defined as a result that either confirmed the null hypothesis or rejected it in favour of the control arm.

Statistical Analysis

We used the χ^2 test to compare publication rates in the registry between trials grouped by funding type. P values of < 0.05 were considered statistically significant. We also used the χ^2 test to compare publication rates in a PRJ between trials grouped by funding type. To test for the effect of this variable on publication, we used adjusted binary logistic regression (non-publication versus publication), which produced an odds ratio (OR) and a 95% confidence interval; an OR larger than 1.0 indicated a greater likelihood of trial publication in this group. The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other). These analyses was pre-specified and undertaken to evaluate whether or not industry funding, enrolment or country had an impact on patterns of publication. Statistical analyses were performed by using R version 3.3.1⁵

RESULTS

Overall, 583 interventional phase 3 and 4 clinical trials met the inclusion criteria. Of these 583 trials, 7 had a “Withdrawn” status and were consequently excluded. Fifty-one were phase 4 trials with the remaining 525 phase 3. A total of 484 (84.0%) of all the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

interventional phase 3 and 4 clinical trials did not publish the compulsory summary results in the ClinicalTrials.gov registry. NIH funding was significantly associated with a higher likelihood of reporting results (OR 3.23, 1.89 to 5.57; $p < 0.001$). Industry funding was likewise significantly associated with a higher likelihood of reporting results in the registry (OR 3.43, 1.93 to 6.08; $p < 0.001$). No statistically significant differences were found between NIH-funded trials and Industry-funded trials (OR = 1.14, 0.64 to 2.04, $p = 0.66$) (See Table 2 and Figure 3). Although we had focus in funding as our explanatory variable we have also observed that, “being from an American Institution” (in Principal Investigator variable) was significantly associated with a higher likelihood of reporting results when adjusted by funding type and enrolment (See Table 3).

When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry, although this percentage difference was not significant (OR 1.75, 0.68 to 5.99; $p = 0.301$)

Overall, 463 interventional phase 3 and 4 clinical trials met the criteria for searching a publication in a PRJ (43 phase 4 trials and 420 phase 3 trials). A total of 255 (55.1%) trials each had at least one publication of their results in a PRJ, but 208 (44.9%) trials remained unpublished. Median and mean time to publication was 60 months. NIH funding was significantly associated with a higher likelihood of published results (OR 3.17, 1.85 to 5.55; $p < 0.001$). Industry funding was not significantly associated with a higher or lower likelihood of publishing results in a peer-reviewed journal (OR 1.14, 0.67 to 1.98; $p = 0.63$) (see Table 4 and Figure 4). “Being from an American Institution” was not significantly associated with a lower or higher likelihood of publishing results when adjusted by funding type and enrolment. (See table 5).

Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished. This difference between phase 3 and phase 4 trials was statistically significant (OR = 2.23, 1.18 to 4.34; p = 0.02).

Of these 463 trials, when taking into account cancer subtype, we found the following percentages for unpublished results in a PRJ (total number of unpublished trials is shown in parentheses): 41.2% for brain (14 of 34), 37.9% for breast (25 of 66), 61.1% for cervical (11 of 18), 37.9% for colorectal (11 of 29), 33.3% for endometrial (3 of 9), 75% for oesophagus (3 of 4), 62.5% for eye (5 of 8), 37.5% for gastric (3 of 8), 55.6% for head and neck (47 of 84), 100.0% for kidney (2 of 2), 36.0% for leukaemia (9 of 25), 50.0% for liver (4 of 8), 48.1% for lung (25 of 52), 100.0% for melanoma (1 of 1), 66.7% for myeloma (2 of 3), 80% for metastasis (4 of 5), 36.4% for pancreatic (4 of 11), 45.2% for prostate (19 of 42), 55.6% for bladder (5 of 9), 33.3% for lymphoma (7 of 21), 33.3% for sarcoma (4 of 12), 61.5% for other (8 of 13). For all subgroups we ran a significance test to determine whether these percentages were different from the global non-publication tendency. As can be seen in Table 6, no statistically significant difference was found in any of them with the exception of head and neck which showed slightly worse numbers

For publication bias, only 67 trials (14.4%) met the criteria: 18 trials reported a summary result but were not published in a PRJ, and 49 trials reported a summary result and were published in a PRJ. For our first subset, 8 of 18 trials (44.4%) showed a positive finding and the remaining 10 (55.6%) a negative finding; the second subset showed a similar pattern: 24 of 49 (49.0%) had a positive finding and the remaining 25 (51%) a negative finding (Table 7).

DISCUSSION

Clinical trials produce the best data available for decision-making in modern evidence-

based medicine. All evidence should be both published and available because withholding the results skews the evidence and therefore dangerously distorts it. When evidence is not published, those who make decisions about potential treatments do not have complete information about the outcome and the entire set of benefits and risks that a particular treatment might involve. The importance of publishing negative results has not been stressed strongly enough⁶; publishing these results not only reduces biases regarding the efficacy of a treatment, but also plays a huge role in helping science to move forward. Perhaps the most famous example of a negative result was the historic paper published by Michelson and Morley in 1883,⁷ which led a young physicist working at a patent office in Bern 22 years later, in 1905, to completely change our notion of space and time—a notion that almost one hundred years later turned out to be an essential feature in the GPS system. This young physicist was Albert Einstein. Despite the importance of knowing whether there is publication bias in radiation oncology, the present work confirms that it is not possible to assess such bias because of a massive lack of data: a mere 15% of the trials registered at ClinicalTrials.gov had published the compulsory summary result and only 45% of all trials conducted had been published in a PRJ. Rates of publication in radiation oncology were nonetheless higher than those previously reported 3 years ago in a cross-sectional analysis of large randomised clinical trials in medicine, although comparisons are hard to make because our work is an observational study in a specific medical field with substantially different inclusion criteria.⁸

As our results showed, a large number of interventional phase 3 and 4 trials in radiation oncology have been conducted but have not published their results. Thus, 45% of all evidence collected in our field is seemingly lost forever and raises the question about the extent to which the treatments being offered to patients are really evidence based. This problem of representation does not only concern radiation oncology, but it has also been a distinctive issue in medicine. Even if our findings are consistent with previously observed

rates of non-publication in other clinical scenarios, our results add to existing work by showing that this representation problem is an essential feature of interventional phase 3 and phase 4 trials in radiation oncology, since studies assessing non-publication did not analyse interventional radiotherapy trials separately.⁹⁻²⁰

It is worth noting that trials funded by NIH and industry showed a higher rate of reporting results in the registry than did other trials, even though nearly 65% of NIH- and industry-funded trials did not report anything in ClinicalTrials.gov. In addition, there was no statistically significant difference between trials funded by private companies or by NIH. One way to improve these reporting rates would be to apply economic sanctions against sponsors who do not comply with the regulation (such sanctions already exist in the USA by the Food and Drug Administration, although they have rarely been applied); however, economic sanctions against clinical investigators or companies might prevent them from deciding to begin a new trial if sanctions are a possibility. Having fewer trials could be damaging to the health system as a whole, as well as to future patients. A potential solution would be to institute a system whereby if clinical investigators apply for public funding, they have to disclose results of all previously conducted trials; for privately funded trials, results from all previous studies would have to be made available before the new trial could be registered.

Recently, it has been reported that fewer than half of the trials funded by NIH were published in a PRJ.⁴ We found a far better publishing rate within the radiation oncology field, since almost 75% of all trials with NIH funding published their results in a PRJ. We found that publication rates for industry-funded trials, on the other hand, were far worse, with 60% of them remaining unpublished. An important consideration is that, leaving aside NIH-funded trials, although this 50% rate of non-publication was higher in industry-funded than in non-industry-funded trials, the differences were not statistically significant. This result is opposite to what has been sometimes reported in the medical literature.²¹

We would like also to mention that Principal Investigators from an American Institution were more likely to report results on ClinicalTrials.gov registry and this might be because the law enforcing the registration and reporting of clinical trial results was an American one.

A study design limitation should be considered when interpreting these results. Although we allowed a minimum 24 months for publication in a PRJ, but we did not know if this period was long enough for an assessment of publication. Since all trials analysed in this study should have reported results after a 12 month period, we decided to allow for another 12 months for publishing in a PRJ. Phase 3 and phase 4 clinical trials provide strong evidence and are more easily accepted for publication in a PRJ. Although a 24 month period might not seem sufficient to our purposes, we have to emphasize that this 24 months was a minimum and most trials analysed in our study were given much more time to publish their results, with a median and mean “time to publication” of 60 months.

It is hard to fathom the reasons underlying this non-publication. One reason might be that we are living in a “publish or perish” era and most clinicians and researchers are willing to participate in a trial without questioning what is really happening with these data globally (there are more ongoing trials than ever before and, as a consequence, it is easy for investigators to participate in multiple trials at the same time; the paradox might rest on the fact that when one of those trials remain unpublished, little attention is paid to it). Another potential reason is publication bias, although it was not possible to assess it in this study. A final possibility is “the planning fallacy”^{22,23}: people tend to make terrible predictions of task completion times and what once looked like a feasible trial becomes a longer and much more difficult project to undertake. Given these possibilities, it is important to highlight initiatives such as the 2013 “Restoring Invisible and Abandoned Trials” statement, which was supported by a number of important journals, giving trialists an amnesty of 1 year to publish the results of previously unreported trials.²⁴

As it has been previously stated in the Methods section we chose ClinicalTrial.gov registry because this registry represented the most comprehensive source for information about ongoing and completed trials within and outside the USA. However, as large and important as this registry is, many trials conducted in radiotherapy have been registered in other registries. Therefore, it should be taken into account that our dataset did not represent the entire population of interventional phase 3 and 4 trials conducted in radiotherapy. On the other hand, we assumed most phases 3 and 4 trials conducted in radiotherapy would be willing to apply their results on the USA soil and therefore have to comply with the FDAAA 801.

There are additional limitations concerning our described search method in ClinicalTrials.gov registry. ClinicalTrials.gov search engine allows the user to focus its search through multiple search fields. Searching for the word “Radiotherapy” did not account for all trials conducted in radiotherapy and produced an enormous amount of false positive results. To account for all this false negative and false positive results we had to extend our search terms further, including radiotherapy-related terms such as “radiation oncology”, “radiation therapy” or “IMRT”. This strategy broadened the initial search and lowered considerably false negative results in our final set, but it is likely that not all phase 3 and phase 4 interventional clinical trials were capture by our search strategy. On the other hand, false positive results were easily handled performing a double check on every item at our final set.

In summary, non-publication means poor use of financial resources from funders, host institutions, and commissioning bodies. It also means loss of knowledge through hidden data, makes medical practice less evidence-based, and risks biasing the evidence in important ways. Moreover, it means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients. This ethical issue should

be at the heart of our current medical practice.

REFERENCES

1. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, *et al*. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med* 2004;351:1250-1.
2. Section 801 of the Food and Drug Administration Amendments Act. SEPT. 27, 2007;121 STAT. 904 PUBLIC LAW 110–85
3. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. WMA General Assembly:1-5.
4. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. *BMJ* 2012;344:d7292
5. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>
6. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. *JAMA Oncol.* 2016 Jul 1;2(7):875-81
7. A. A. Michelson and E. W. Morley. On the relative motion of the Earth and the luminiferous ether. *Am J Sci.* November 1887 Series 3 Vol. 34:333-345;
8. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. *BMJ* 2013; 347:f6104
9. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008;358:252-60.

10. Turner EH, Knoopfmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS Med* 2012;9:e1001189

11. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. *JAMA* 2003;290:495-501.

12. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. *Ann Intern Med* 2010;153:158-66.

13. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. *PLoS Med* 2009;6:e1000144.

14. Chan AW, Krlaza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. *CMAJ* 2004;171:735-40.

15. Von Elm E, Rollin A, Blumle A, Huwiler K, Witschi M, Egger M. Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. *Swiss Med Wkly* 2008;138:197-203.

16. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. *PLoS Med* 2008;5:e191.

17. Schmucker C, Schell LK, Portalupi S, Oeller P, Cabrera L, Bassler et a. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. *PLoS One* 2014; 9(12):e114023

18. Shiles C, Sinclair J. It's never too late to publish an abandoned trial. *F1000Res* 2015; 4:120

19. Brænd AM, Straand J, Jakobsen RB, Klovning A. Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice. *BMJ Open* 2016; 6(4):e010535

20. Thompson AC, Petit-Zeman S, Goldacre B, Heneghan CJ. Getting our house in order: an audit of the registration and publication of clinical trials supported by the National In-

stitute of Health Research Oxford Biomedical Research Centre and the Musculoskeletal Biomedical Research Unit. *BMJ Open* 2016; 6(3):e009285

21. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A. Discontinuation and non-publication of surgical randomised controlled trials: observational study. *BMJ*. 2014 Dec 9;349:g6870
22. Kahneman D, Tversky A. Intuitive prediction: biases and corrective procedures. *TIMS Studies in Management Science*, 1979; 12,313-327.
23. Buehler R, Griffin D, Ross M. Exploring the "Planning Fallacy": Why People Underestimate Their Task Completion Times. *Journal of Personality and Social Psychology*, 1994; Vol.67. No 3. 366-381
24. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ* 2013; 346:f2865

AUTHOR'S CONTRIBUTIONS

JP-A and PG conceptualised and designed the study. JP-A and PG wrote the first draft of the manuscript. IL, EA, JP-A and PG conducted and analysed registry and peer-reviewed journal searches. AP reviewed the manuscript and helped with the interpretation of the data. All authors approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest for the present research.

FUNDING

The authors did not receive funding of any kind for this research.

Data Sharing Statement

All data used in this research are publicly available from Clinicaltrials.gov, with the inclusion criteria cited in the text.

ClinicalTrials.gov’s API Information

Information extracted			
NCT Number	Gender	Other IDs	Results First Received
Title	Age Groups	First Received	Primary Completion Date
Recruitment	Phases	Start Date	Outcome Measures
Study Results	Enrollment	Completion Date	URL
Conditions	Funded Bys	Last Updated	
Interventions	Study Types	Last Verified	
Sponsor/Collaborators	Study Designs	Acronym	

Table 1. Information extracted for each interventional Phase 3 and Phase 4 trial.

Summary of Results posted on the ClinicalTrial.gov registry

	Number of trials	Results NOT posted on ClinicalTrials.gov registry
Phase 3	525	438 (83.4 %)
Phase 4	51	46 (90.2 %)
NIH-Funded	146	93 (63.7 %)
Industry-Funded	85	56 (65.9 %)
Other-Funded	502	450 (89.6 %)
Total	576	484 (84.0 %)

Table 2. Number of trials with results not posted on ClinitalTrials.gov registry. Funded feature is not an exclusive one: trials might have been funded by a combination of the three possible options (NIH, Industry and Other).

	Being from an American Institution p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p < 0.001 OR 3.54, 2.06 to 6.16	p = 0.011 OR 1.00, 1.00 to 1.00
Industry-Funded	p < 0.001 OR 5.98, 3.68 to 9.94	p = 0.06 OR 1.00, 0.99 to 1.00
Other-Funded	p < 0.001 OR 6.70, 3.99 to 11.58	p = 0.27 OR 1.00, 0.99 to 1.00

Table 3 Adjusted binary logistic regression (non-publication versus publication in ClinicalTrials.gov) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal

	Number of trials	Results NOT published on PRJ
Phase 3	420	181 (43.1 %)
Phase 4	43	27 (62.8 %)
NIH-Funded	113	30 (26.5 %)
Industry-Funded	64	26 (40.6 %)
Other-Funded	412	189 (45.9%)
Total	463	208 (44.9%)

Table 4. Number of trials with Results not published on a PRJ. As in Table 1, the Funded feature is not exclusive, and there might be trials which were funded by a combination of the three possible options (NIH, Industry and Other).

PRJ

	Being from an American Institution p-value and OR (CI 95%)	Enrollment p-value and OR (CI 95%)
NIH-Funded	p = 0.691 OR 0.91, 0.56 to 1.46	p = 0.07 OR 1.00, 0.99 to 1.00
Industry-Funded	p = 0.052 OR 1.50, 1.00 to 2.26	p = 0.087 OR 1.00, 0.99 to 1.00
Other-Funded	p = 0.054 OR 1.49, 0.99 to 2.25	p = 0.117 OR 1.00, 0.99 to 1.00

Table 5 Adjusted binary logistic regression (non-publication versus publication in PRJ) by funding type, adjusted for the country of the Principal Investigator and Enrollment.

Summary of Results published on a Peer Review Journal by cancer subtype

	Number of tri- als	Results NOT published on PRJ	Odds Ratio (CI 95%)	p-value
Brain	34	14 (41.2%)	0.85 (0.42 to 1..72)	0.65
Breast	66	25 (37.9%)	0.71 (0.42 to 1.22)	0.21
Cervical	18	11 (61.1%)	1.98 (0.75 to 5.20)	0.16
Colorectal	29	11 (37.9%)	0.74 (0.34 to 1.59)	0.43
Endometrial	9	3 (33.3%)	0.61 (0.15 to 2.46)	0.48
Esophagus	4	3 (75%)	3.72 (0.38 to 36)	0.22
Eye	8	5 (62.5%)	2.07 (0.49 to 8.76)	0.31
Gastric	8	3 (37.5%)	0.73 (0.17 to 3.10)	0.67
Head&Neck	84	47 (55.6%)	1.72 (1.07 to 2.77)	0.03
Kidney	2	2 (100.0%)	NaN	0.12
Leukemia	25	9 (36.0%)	0.68 (0.29 to 1.56)	0.36
Liver	8	4 (50.0%)	1.23 (0.30 to 4.98)	0.77
Lung	52	25 (48.1%)	1.15 (0.65 to 2.06)	0.63
Melanoma	1	1 (100.0%)	NaN	0.27
Metastasis	5	4 (80.0%)	4.98 (0.55 to 44.9)	0.11
Myeloma	3	2 (66.7%)	2.47 (0.22 to 27.39)	0.44
Pancreatic	11	4 (36.4%)	0.69 (0.20 to 2.41)	0.56
Prostate	42	19 (45.2%)	1.01 (0.54 to 1.92)	0.97
Bladder	9	5 (55.5%)	1.55 (0.41 to 5.83)	0.52
Lymphoma	21	7 (33.3%)	0.60 (0.24 to 1.51)	0.27
Sarcoma	12	4 (33.3%)	0.61 (0.18 to 2.04)	0.41
Other	13	8 (61.5%)	2 (0.64 to 6.21)	0.22

Table 6. Number of trials with results not published in a PRJ by cancer subtype. For those subgroups with at least 16 trials we run a significant test in order to see if these percentages were different from the global non-publication tendency. For each cancer subtype odds ratio were calculated taking as reference the global set minus this cancer subtype subset.

Publication Bias Analysis			
	Number of trials	Positive Results	Negative Results
Results published on PRJ	18	8 (44.4%)	10 (55.6%)
Results NOT published on PRJ	49	24 (49.0%)	25 (51%)
Results	67	32 (47.8%)	35 (52.2%)

Table 7. Number of trials meeting the inclusion criteria for analyzing the publication bias.

Figure legends

- Figure 1: Database search
- Figure 2: Publication search in a PRJ
- Figure 3 : Distribution of trials in table 2
- Figure 4 : Distribution of trials in table 4




Figure 1: Database search

181x222mm (96 x 96 DPI)




Figure 2: Publication search in a PRJ

181x222mm (96 x 96 DPI)




Figure 3 : Distribution of trials in table 2

705x478mm (72 x 72 DPI)




Figure 4 : Distribution of trials in table 4
705x478mm (72 x 72 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
Title and abstract	1	<p>(a) Indicate the study's design with a commonly used term in the title or the abstract PUBLICATION OF INTERVENTIONAL PHASE 3 AND 4 CLINICAL TRIALS IN RADIATION ONCOLOGY: AN OBSERVATIONAL STUDY</p> <hr/> <p>(b) Provide in the abstract an informative and balanced summary of what was done and what was found. Page 2.</p>
Introduction		
Background/rationale	2	<p>Explain the scientific background and rationale for the investigation being reported</p> <p>Page 4: Clinical trials produce the best data available for decision-making in modern evidence-based medicine. All this evidence should be both published and available, since withholding results skews the evidence and therefore dangerously distorts it. Publication of all trials conducted in radiation oncology is needed to fully determine the benefits and risks of treatments currently in use in our clinics.</p>
Objectives	3	<p>State specific objectives, including any prespecified hypotheses</p> <p>Page 4: In this work, we answered two important questions regarding the state of the evidence in radiation oncology. The first was, "Were the trials conducted in radiation oncology in compliance with the US law and therefore did they make their results publicly available?" The second was "How many of the trials conducted in radiation oncology have published their results in a peer-reviewed journal (PRJ)?" The answers to both questions are vital to our patients, to our health care system (independently of the model a country has chosen as its own), and to the state of evidence we have within our reach as practitioners (are our treatments really based on evidence?).</p>
Methods		
Study design	4	<p>Present key elements of study design early in the paper Page 5: the key elements of the study are presented: The detailed search in the ClinicaTrials.gov database, and the criteria to classify the trials.</p>
Setting	5	<p>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</p> <p>This item is not directly applicable to our study. However, if we understand participants as trials, the relevant dates and settings are described in Page 5-8:</p> <p>We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015.</p> <p>Because our query on ClinicalTrials.gov was conducted on 6 May 2016, we allowed a minimum of 24 months after the latest possible PCD (6 May 2014) for journal submission, peer review and editorial process until the trial was finally published in a PRJ.</p>

Participants	6	<p>(a) Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>Page 5-6: For this study and within the aforementioned date range, we considered all clinical trials that met the following criteria:</p> <ul style="list-style-type: none">• Study type: Interventional studies• Interventions: Radiotherapy as standard treatment or primary focus in oncology• Phase: Phase 3; Phase 4. <p>Trials with a “Withdrawn” status were excluded because these trials have ended early before enrolling the first patients.</p>
Variables	7	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</p> <p>Page 7 : Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.</p> <p>Page 7 : Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:</p> <ul style="list-style-type: none">• The trial was published in a PRJ. <p>Page 8 : In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ.</p>
Data sources/ measurement	8*	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p> <p>Page 5 : We searched the ClinicalTrials.gov database for trials in radiotherapy as of 6 May 2016 that had a PCD between 1 January 2008 and 1 January 2015. When a PCD was missing, we instead used the completion date field. We used the “Advanced Search” form to broaden our search. We filled in all the fields below as follows:</p> <ul style="list-style-type: none">• Search Terms: “Radiotherapy” OR “Radiation Therapy” OR “Brachytherapy” OR “IMRT” OR “SBRT” OR “IMPT” OR “Radiation Oncology” [IMRT stands for Intensity-Modulated Radiation Therapy; SBRT stands for Stereotactic Body Radiation Therapy; IMPT stands for Intensity-Modulated Proton Therapy]• Study Type: Interventional Studies• Study Results: All Studies• Recruitment: All Studies• Additional Criteria → Phase: No Phase was ticked since phase 3 or 4 trials concerning radiation therapy were also registered as trials without phase.

Bias

9 Describe any efforts to address potential sources of bias

Page 7: Each author searched PubMed, Google Scholar, and Google by using the following characteristics: NCT number, other identification numbers provided by ClinicalTrials.gov, author names, institutions, title, official title, and keywords. Matches were evaluated according to title, trial design, sample size, intervention, location, dates of recruitment and completion, study hypotheses, and primary and/or secondary outcome measures, as described in the ClinicalTrials.gov database. Matches found by each researcher were always checked by a second researcher. We then categorised our data into subsets by cancer subtype.

Study size 10 Explain how the study size was arrived at

This item is not directly applicable to our study

Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why

Page 6: Finally, we analysed the “Study Results” field and differentiated between those studies with a “Has Results” tag from those with a “No Results Available” tag.

Page 7: Our clinical trial set was divided into four subsets. Each subset was given to a particular researcher (JPA, PGF, ILG, EAR). A trial was considered published if it met the following criteria:

- The trial was published in a PRJ.

Page 8: In order to look for publication bias, we took into account all trials with results in the registry that qualified for a search in a PRJ. This set was further divided into two subsets: the first contained all trials with a summary result reported in the registry and no publication in a PRJ; the second contained all trials with a summary result reported in the registry and a publication in a PRJ. For each subset, we further analyse positive and negative result frequencies. A positive finding was defined as a result rejecting the null hypothesis in favour of the experimental arm; a negative finding, on the other hand, was defined as a result that either confirmed the null hypothesis or rejected it in favour of the control arm.

Statistical methods 12

(a) Describe all statistical methods, including those used to control for confounding

(b) Describe any methods used to examine subgroups and interactions

(c) Explain how missing data were addressed

(d) If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

Page 8-9:

We used the χ^2 test to compare publication rates in the registry between trials grouped by funding type. P values of < 0.05 were considered statistically significant. We also used the χ^2 test to compare publication rates in a PRJ between trials grouped by funding type. To test for the effect of this variable on publication, we used adjusted binary logistic regression (non-publication versus publication), which produced an odds ratio (OR) and a 95% confidence interval; an OR larger than 1.0 indicated a greater likelihood of trial publication in this group. The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other). These analyses were pre-specified and undertaken to evaluate whether or not industry funding, enrolment or country had an impact on patterns of publication. Statistical analyses were performed

by using R version 3.3.1⁵

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>Page 9: Overall, 583 interventional phase 3 and 4 clinical trials met the inclusion criteria. Of these 583 trials.... Fifty-one were phase 4 trials with the remaining 525 phase 3... Overall, 463 interventional phase 3 and 4 clinical trials met the criteria for searching a publication in a PRJ (43 phase 4 trials and 420 phase 3 trials)... Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished...</p> <p>(b) Give reasons for non-participation at each stage</p> <p>Not applicable</p> <p>(c) Consider use of a flow diagram</p> <p>We have addressed two Venn’s diagrams to clarify the trials categories.</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>Not applicable</p> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Not applicable</p>
Outcome data	15*	<p>Report numbers of outcome events or summary measures</p> <p>Page 9 :</p> <p>Fifty-one were phase 4 trials with the remaining 525 phase 3. A total of 484 (84.0%) of all the interventional phase 3 and 4 clinical trials did not publish the compulsory summary results in the ClinicalTrials.gov registry</p> <p>When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry,</p> <p>Taking into account the trial phase, 27 (62.8%) phase 4 trials and 181 (43.1%) phase 3 trials remained unpublished.</p> <p>Of these 463 trials, when taking into account cancer subtype, we found the following percentages for unpublished results in a PRJ (total number of unpublished trials is shown in parentheses): 41.2% for brain...</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Page 9: The main explanatory variable was funding status adjusted for number of patients in the trial and the country of the Principal Investigator (American Institution versus Other).</p> <p>Page 9: NIH funding was significantly associated with a higher likelihood of reporting results (OR 3.23, 1.89 to 5.57; p < 0.001).</p>

Industry funding was likewise significantly associated with a higher likelihood of reporting results in the registry (OR 3.43, 1.93 to 6.08; $p < 0.001$). No statistically significant differences were found between NIH-funded trials and Industry-funded trials (OR = 1.14, 0.64 to 2.04, $p = 0.66$)

When categorised by phase, 46 (90.2%) phase 4 trials and 438 (83.4%) phase 3 trials did not publish a deposition of their results in the registry, although this percentage difference was not significant (OR 1.75, 0.68 to 5.99; $p = 0.301$)

NIH funding was significantly associated with a higher likelihood of published results (OR 3.17, 1.85 to 5.55; $p < 0.001$). Industry funding was not significantly associated with a higher or lower likelihood of publishing results in a peer-reviewed journal (OR 1.14, 0.67 to 1.98; $p = 0.63$) (see Table 4 and Figure 2). “Being American” was not significantly associated with a lower or higher likelihood of published results when adjusted by funding type and enrolment. (See table 5).

(b) Report category boundaries when continuous variables were categorized

Not applicable

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Not applicable

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
----------------	----	--

Page 11: For publication bias, only 67 trials (14.4%) met the criteria: 18 trials reported a summary result but were not published in a PRJ, and 49 trials reported a summary result and were published in a PRJ. For our first subset, 8 of 18 trials (44.4%) showed a positive finding and the remaining 10 (55.6%) a negative finding; the second subset showed a similar pattern: 24 of 49 (49.0%) had a positive finding and the remaining 25 (51%) a negative finding (Table 7).

Discussion

Key results	18	Summarise key results with reference to study objectives
-------------	----	--

Page 12: Despite the importance of knowing whether there is publication bias in radiation oncology, the present work confirms that it is not possible to assess such bias because of a massive lack of data: a mere 15% of the trials registered at ClinicalTrials.gov had published the compulsory summary result and only 45% of all trials conducted had been published in a PRJ.

Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
-------------	----	--

Page 14-15: As it has been previously stated in the Background section we chose ClinicalTrials.gov registry because this registry represented the most comprehensive source for information about ongoing and completed trials within and outside the USA. However, as large and important as this registry is, many trials conducted in radiotherapy have been registered in other registries. Therefore, it should be taken into account that our dataset did not represent the entire population of interventional phase 3 and 4 trials conducted in radiotherapy. On the other hand, we assumed most phases 3 and 4 trials conducted in radiotherapy would be willing to apply their results on the USA soil and therefore have to comply with the FDAAA 801, There was also a limitation of our search method due to a limitation of the

ClinicalTrials.gov search engine. Although search results displayed by the registry depend on the selection of words made, radiotherapy trials were not uniquely identified by the term “radiotherapy”. When using only “radiotherapy” in the search box, we discovered a high percentage of false positive results. The same was true when using other search terms as “Radiation Therapy” or “Radiation Oncology”. In order to account for this we had to double-check manually every result display in the search result. We performed multiple searches with different search terms in order to register as many as possible radiotherapy trials, but some of them might have slipped our search method even if they were registered in ClinicalTrials.gov.

Interpretation	20	<p>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</p> <p>Page 15: In summary, non-publication means poor use of financial resources from funders, host institutions, and commissioning bodies. It also means loss of knowledge through hidden data, makes medical practice less evidence-based, and risks biasing the evidence in important ways. Moreover, it means that a large number of study participants were exposed to the risks of trial participation without the supposed benefits that sharing and publishing of results would offer to future generations of patients. This ethical issue should be at the heart of our current medical practice.</p>
Generalisability	21	<p>Discuss the generalisability (external validity) of the study results</p> <p>Page 12: Rates of publication in radiation oncology were nonetheless higher than those previously reported 3 years ago in a cross-sectional analysis of large randomised clinical trials in medicine, although comparisons are hard to make because our work is an observational study in a specific medical field with substantially different inclusion criteria.⁸</p>
Other information		
Funding	22	<p>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based</p> <p>Not applicable.</p>

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.